{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:28:08Z","timestamp":1760131688739},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,12,10]],"date-time":"2004-12-10T00:00:00Z","timestamp":1102636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1007\/s00520-004-0730-2","type":"journal-article","created":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T10:44:02Z","timestamp":1110278642000},"page":"145-152","source":"Crossref","is-referenced-by-count":36,"title":["Contribution to variability in response to opioids"],"prefix":"10.1007","volume":"13","author":[{"given":"Geoffrey W.","family":"Hanks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colette","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,12,10]]},"reference":[{"key":"CR1","first-page":"with","volume":"relief","author":"World","year":"1996","unstructured":"World Health Organization (1996) Cancer pain relief: with a guide to opioid availability. World Health Organization, Geneva","journal-title":"Cancer pain"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1191\/0269216304pm897ed","volume":"18","author":"Reid","year":"2004","unstructured":"Reid C, Davies A (2004) The World Health Organization three-step analgesic ladder comes of age. Palliat Med 18:175?176","journal-title":"Palliat Med"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.1995.03530230056031","volume":"274","author":"Jadad","year":"1995","unstructured":"Jadad AR, Browman GP (1995) The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274:1870?1873","journal-title":"JAMA"},{"key":"CR4","first-page":"823","volume":"7034","author":"Expert","year":"1996","unstructured":"Expert Working Group of the European Association for Palliative Care (1996) Morphine in cancer pain: modes of administration. BMJ 312:823?826","journal-title":"BMJ"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(87)91083-X","volume":"8561","author":"Hanks","year":"1987","unstructured":"Hanks GW, Hoskin PJ, Aherne GW, Turner P, Poulain P (1987) Explanation for potency of repeated oral doses of morphine? Lancet 2:723?725","journal-title":"Lancet"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2125.1989.tb05399.x","volume":"4","author":"Hoskin","year":"1989","unstructured":"Hoskin PJ, Hanks GW, Aherne GW, Chapman D, Littleton P, Filshie J (1989) The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 27:499?505","journal-title":"Br J Clin Pharmacol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-199101000-00001","volume":"1","author":"Glare","year":"1991","unstructured":"Glare PA, Walsh TD (1991) Clinical pharmacokinetics of morphine. Ther Drug Monit 13:1?23","journal-title":"Ther Drug Monit"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0885-3924(93)90101-Z","volume":"2","author":"Poyhia","year":"1993","unstructured":"Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone?s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8:63?67","journal-title":"J Pain Symptom Manage"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/clpt.1992.176","volume":"5","author":"Leow","year":"1992","unstructured":"Leow KP, Smith MT, Williams B, Cramond T (1992) Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52:487?495","journal-title":"Clin Pharmacol Ther"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/ajhp\/59.21.2061","volume":"21","author":"Ma","year":"2002","unstructured":"Ma MK, Woo MH, McLeod HL (2002) Genetic basis of drug metabolism. Am J Health Syst Pharm 59:2061?2069","journal-title":"Am J Health Syst Pharm"},{"key":"CR11","first-page":"768","volume":"6","author":"Wu","year":"1997","unstructured":"Wu D, Kang YS, Bickel U, Pardridge WM (1997) Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos 25:768?771","journal-title":"Drug Metab Dispos"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1620\/tjem.105.45","volume":"1","author":"Shimomura","year":"1971","unstructured":"Shimomura K, Kamata O, Ueki S, Ida S, Oguri K (1971) Analgesic effect of morphine glucuronides. Tohoku J Exp Med 105:45?52","journal-title":"Tohoku J Exp Med"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1067\/mcp.2000.111934","volume":"6","author":"Penson","year":"2000","unstructured":"Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML (2000) Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 68:667?676","journal-title":"Clin Pharmacol Ther"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.292.6535.1548","volume":"J","author":"Osborne","year":"1986","unstructured":"Osborne RJ, Joel SP, Slevin ML (1986) Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 292:1548?1549","journal-title":"Br Med"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3959(91)90005-I","volume":"1","author":"Portenoy","year":"1991","unstructured":"Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Layman M, Cerbone DF, Inturrisi CE (1991) Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 47:13?19","journal-title":"Pain"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0885-3924(91)90961-3","volume":"3","author":"Hagen","year":"1991","unstructured":"Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE (1991) Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 6:125?128","journal-title":"J Pain Symptom Manage"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/107385840100700307","volume":"3","author":"Pasternak","year":"2001","unstructured":"Pasternak GW (2001) The pharmacology of mu analgesics: from patients to genes. Neuroscientist 7:220?231","journal-title":"Neuroscientist"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00008571-200201000-00002","volume":"1","author":"Lotsch","year":"2002","unstructured":"Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G (2002) The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12:3?9","journal-title":"Pharmacogenetics"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-200201000-00001","volume":"1","author":"Hollt","year":"2002","unstructured":"Hollt V (2002) A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 12:1?2","journal-title":"Pharmacogenetics"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0024-3205(95)00311-S","volume":"6","author":"Bartlett","year":"1995","unstructured":"Bartlett SE, Smith MT (1995) The apparent affinity of morphine-3-glucuronide at mu1-opioid receptors results from morphine contamination: demonstration using HPLC and radioligand binding. Life Sci 57:609?615","journal-title":"Life Sci"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-0773.1994.tb00327.x","volume":"2","author":"Bartlett","year":"1994","unstructured":"Bartlett SE, Dodd PR, Smith MT (1994) Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol 75:73?81","journal-title":"Pharmacol Toxicol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/009127007701700402","volume":"4","author":"Beaver","year":"1977","unstructured":"Beaver WT, Wallenstein SL, Houde RW, Rogers A (1977) Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 17:186?198","journal-title":"J Clin Pharmacol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9236(98)90051-0","volume":"6","author":"Heiskanen","year":"1998","unstructured":"Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603?611","journal-title":"Clin Pharmacol Ther"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","volume":"6","author":"Poyhia","year":"1992","unstructured":"Poyhia R, Seppala T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617?621","journal-title":"Br J Clin Pharmacol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0952-8180(95)00092-5","volume":"1","author":"Kirvela","year":"1996","unstructured":"Kirvela M, Lindgren L, Seppala T, Olkkola KT (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13?18","journal-title":"J Clin Anesth"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/clpt.1993.43","volume":"4","author":"Otton","year":"1993","unstructured":"Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (1993) Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53:401?409","journal-title":"Clin Pharmacol Ther"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/00498250110119090","volume":"5","author":"Zheng","year":"2002","unstructured":"Zheng M, McErlane KM, Ong MC (2002) Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient. Xenobiotica 32:427?439","journal-title":"Xenobiotica"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0024-3205(01)01133-X","volume":"4","author":"Wright","year":"2001","unstructured":"Wright AW, Mather LE, Smith MT (2001) Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 69:409?420","journal-title":"Life Sci"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1191\/026921601669626431","volume":"1","author":"Lee","year":"2001","unstructured":"Lee MA, Leng ME, Tiernan EJ (2001) Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 15:26?34","journal-title":"Palliat Med"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/clpt.1980.138","volume":"28","author":"McClain","year":"1980","unstructured":"McClain DA, Hug CC (1980) Intravenous fentanyl kinetics. Clin Pharmacol Ther 28:106?114","journal-title":"Clin Pharmacol Ther"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2165\/00003088-198308050-00004","volume":"8","author":"Mather","year":"1983","unstructured":"Mather LE (1983) Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 8:422?446","journal-title":"Clin Pharmacokinet"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/cpt1972136923","volume":"13","author":"Inturrisi","year":"1972","unstructured":"Inturrisi CE, Verebely K (1972) Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 18:923?930","journal-title":"Clin Pharmacol Ther"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1021\/jm00285a004","volume":"14","author":"Pohland","year":"1971","unstructured":"Pohland A, Boaz HE, Sullivan HR (1971) Synthesis and identification of metabolites resulting from the biotransformation of d,1-methadone in man and in the rat. J Med Chem 14:194?197","journal-title":"J Med Chem"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1200\/JCO.1998.16.10.3216","volume":"16","author":"Ripamonti","year":"1988","unstructured":"Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1988) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216?3221","journal-title":"J Clin Oncol"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","volume":"9","author":"Cherny","year":"2001","unstructured":"Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542?2554","journal-title":"J Clin Oncol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G","volume":"9","author":"Mercadante","year":"1999","unstructured":"Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856?1866","journal-title":"Cancer"},{"key":"CR37","unstructured":"Gaveriaux-Ruff C, Kieffer BL (1999) Opioid receptors: gene structure and function. In: Stein C (ed) Opioids in pain control: basic and clinical aspects. Cambridge University Press, Cambridge, pp 1?20"},{"key":"CR38","unstructured":"Knapp RJ, Porreca F, Burks TF, Yamamura HI (1989) Mediation of analgesia by multiple opioid receptors. In: Hill CS, Fields WS (eds) Advances in pain research and therapy. Raven Press, New York, pp 247?289"},{"key":"CR39","first-page":"378","volume":"5","author":"de","year":"1995","unstructured":"de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378?384","journal-title":"J Pain Symptom Manage"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/026921639801200114","volume":"1","author":"Hawley","year":"1998","unstructured":"Hawley P, Forbes K, Hanks GW (1998) Opioids, confusion and opioid rotation. Palliat Med 12:63?64","journal-title":"Palliat Med"},{"key":"CR41","first-page":"1048","volume":"8","author":"Massie","year":"1983","unstructured":"Massie MJ, Holland J, Glass E (1983) Delirium in terminally ill cancer patients. Am J Psychiatry 140:1048?1050","journal-title":"Am J Psychiatry"},{"key":"CR42","first-page":"5","volume":"21","author":"Dickenson","year":"1994","unstructured":"Dickenson AH (1994) Neurophysiology of opioid poorly responsive pain. Cancer Surv 21:5?16","journal-title":"Cancer Surv"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3959(01)00337-2","volume":"1","author":"Yashpal","year":"2001","unstructured":"Yashpal K, Fisher K, Chabot JG, Coderre TJ (2001) Differential effects of NMDA and group I mGluR antagonists on both nociception and spinal cord protein kinase C translocation in the formalin test and a model of neuropathic pain in rats. Pain 94:17?29","journal-title":"Pain"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10298420290023954","volume":"4","author":"Trujillo","year":"2002","unstructured":"Trujillo KA (2002) The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity. Neurotox Res 4:373?391","journal-title":"Neurotox Res"},{"key":"CR45","doi-asserted-by":"crossref","unstructured":"Bell R, Eccleston C, Kalso E (2003) Ketamine as an adjuvant to opioids for cancer pain. Cochrane Library","DOI":"10.1002\/14651858.CD003351"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0140-6736(84)91980-9","volume":"8392","author":"Hanks","year":"1984","unstructured":"Hanks GW, Twycross RG (1984) Pain, the physiological antagonist of opioid analgesics. Lancet 1:1477?1478","journal-title":"Lancet"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0014-2999(78)90114-0","volume":"3","author":"Colpaert","year":"1978","unstructured":"Colpaert FC, Niemegeers CJ, Janssen PA (1978) Nociceptive stimulation prevents development of tolerance to narcotic analgesia. Eur J Pharmacol 49:335?336","journal-title":"Eur J Pharmacol"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3959(95)00088-7","volume":"1","author":"Borgbjerg","year":"1996","unstructured":"Borgbjerg FM, Nielsen K, Franks J (1996) Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers. Pain 64:123?128","journal-title":"Pain"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2044.1981.tb08596.x","volume":"36","author":"Hanks","year":"1981","unstructured":"Hanks GW, Twycross RG, Lloyd JW (1981) Unexpected complication of successful nerve block: morphine induced respiratory depression following removal of severe pain. Anaesthesia 36:37?39","journal-title":"Anaesthesia"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-004-0730-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-004-0730-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-004-0730-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:59:08Z","timestamp":1559095148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-004-0730-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,10]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s00520-004-0730-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,10]]}}}